MARKET

MNLO

Menlo
MNLO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-2.0651
27.26
14.98
1,071,543,029.85
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Zacks.com · 08/12 14:15
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks.com · 08/05 19:01
Were Hedge Funds Right About Piling Into Menlo Therapeutics Inc. (MNLO)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 08/07/2020 13:03
Menlo Therapeutics EPS misses by $0.93, beats on revenue
Menlo Therapeutics (NASDAQ:MNLO): Q2 GAAP EPS of -$1.21 misses by $0.93. Revenue of $11.7M beats by $9.66M. Shares -1.9% PM. Press Release
seekingalpha · 08/06/2020 16:13
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06/2020 15:25
Menlo Therapeutics Shares Up ~16% Following 13G Filing From Perceptive Advisors That Showed 14% Stake In Co.
Benzinga · 06/12/2020 14:05
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead
Seeking Alpha - Article · 06/08/2020 20:10
Menlo Therapeutics drops 17% after pricing equity offering
Menlo Therapeutics (NASDAQ:MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500. Underwr
seekingalpha · 06/05/2020 16:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNLO. Analyze the recent business situations of Menlo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNLO stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 23.88M
% Owned: 46.36%
Shares Outstanding: 167.69M
TypeInstitutionsShares
Increased
16
1.22M
New
16
2.01M
Decreased
23
6.33M
Sold Out
34
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
President/Chief Executive Officer/Director
David Domzalski
Chief Financial Officer/Treasurer
Tyler Zeronda
Chief Technology Officer
Garrett Galley
Chief Scientific Officer
Iain Stuart
General Counsel/Secretary
Mutya Harsch
Other
Matthew Wiley
Lead Director/Independent Director
Patrick Lepore
Director
Steven Basta
Independent Director
Sharon Barbari
Independent Director
Rex Bright
Independent Director
Anthony Bruno
Independent Director
Elisabeth Sandoval
No Data

Webull offers kinds of Menlo stock information, including NASDAQ:MNLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNLO stock methods without spending real money on the virtual paper trading platform.